psoromic acid profile

Psoromic acid is a secondary metabolite produced by various lichen species, including *Cladonia* and *Usnea*. It exhibits a broad range of biological activities, including antibacterial, antifungal, antiviral, and anticancer properties. Research on psoromic acid focuses on understanding its mode of action, exploring its potential applications in medicine, and investigating its role in lichen symbiosis. Its biosynthesis pathway involves the condensation of orsellinic acid and a polyketide chain. Psoromic acid is typically extracted from lichens using organic solvents and purified using chromatographic techniques. Studies have shown that psoromic acid can inhibit the growth of various bacteria, fungi, and viruses, including *Staphylococcus aureus*, *Candida albicans*, and *Herpes simplex virus*. Additionally, psoromic acid has demonstrated cytotoxic activity against certain cancer cell lines. However, further research is needed to evaluate its safety and efficacy in humans. The study of psoromic acid is driven by its potential as a source of novel therapeutic agents.'

psoromic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	23725
CHEMBL ID	176570
CHEBI ID	92074
SCHEMBL ID	2113679
MeSH ID	M0576513

Synonym
DIVK1C_006382
KBIO1_001326
nsc 92186
11h-dibenzo(b,e)(1,4)dioxepin-6-carboxylic acid, 4-formyl-3-hydroxy-8-methoxy-1,9-dimethyl-11-oxo-
SPECTRUM_000493
NCGC00178916-01
10-formyl-9-hydroxy-3-methoxy-4,7-dimethyl-6-oxo-benzo[b][1,4]benzodioxepine-1-carboxylic acid
4-formyl-3-hydroxy-8-methoxy-1,9-dimethyl-11-oxodibenzo[b,f]1,4-dioxepin-6-carboxylic acid
parellic acid
7299-11-8
psoromic acid
nsc92186
psoromic acid (parellic acid)
nsc-92186
SPECTRUM5_000187
BSPBIO_001900
smr000470881
MLS000563148
KBIO2_003541
KBIO2_006109
KBIOGR_002087
KBIOSS_000973
KBIO2_000973
KBIO3_001120
SPECPLUS_000286
SPECTRUM4_001484
SPECTRUM3_000160
NCIOPEN2_009926
SPECTRUM2_000214
SPBIO_000227
10-formyl-9-hydroxy-3-methoxy-4,7-dimethyl-6-oxobenzo[b][1,4]benzodioxepine-1-carboxylic acid
CHEMBL176570 ,
bdbm50056939
cid_23725
parellic acid, 3
4-formyl-3-hydroxy-8-methoxy-1,9-dimethyl-11-oxo-11h-dibenzo[b,e][1,4]dioxepine-6-carboxylic acid
FUCWJKJZOHOLEO-UHFFFAOYSA-N
HMS2268L13
CCG-38361
DTXSID70223264
SCHEMBL2113679
psoromicacid
10-formyl-9-hydroxy-6-keto-3-methoxy-4,7-dimethyl-benzo[b][1,4]benzodioxepin-1-carboxylic acid
mfcd00046941
CHEBI:92074
AKOS030632334
FT-0700762
10-formyl-9-hydroxy-3-methoxy-4,7-dimethyl-6-oxo-1-benzo[b][1,4]benzodioxepincarboxylic acid
Q27163869
4-formyl-3-hydroxy-8-methoxy-1,9-dimethyl-11-oxo-11h-dibenzo[b,e][1,4]dioxepin-6-carboxylic acid
HY-130199
CS-0105660

Class	Description
carbonyl compound	Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
GLS protein	Homo sapiens (human)	Potency	5.6234	0.3548	7.9355	39.8107	AID624170
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	1.1220	0.7079	12.1943	39.8107	AID720542
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	79.4328	0.3548	28.0659	89.1251	AID504847
parathyroid hormone/parathyroid hormone-related peptide receptor precursor	Homo sapiens (human)	Potency	50.1187	3.5481	19.5427	44.6684	AID743266
TAR DNA-binding protein 43	Homo sapiens (human)	Potency	11.2202	1.7783	16.2081	35.4813	AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAD51	Homo sapiens (human)	IC50 (µMol)	45.2260	1.3990	17.7214	32.1000	AID1435; AID1436
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12	IC50 (µMol)	200.0000	0.0050	1.5765	10.0000	AID751284
Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)	IC50 (µMol)	125.0000	0.0010	0.9798	4.5000	AID1799757
Integrase	Human immunodeficiency virus 1	IC50 (µMol)	12.4250	0.0005	1.5443	10.0000	AID93700; AID93702; AID93705; AID93707
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid biosynthetic process	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
fatty acid elongation	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
protein homotetramerization	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
fatty acid biosynthetic process	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
biotin biosynthetic process	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
fatty acid elongation	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
response to antibiotic	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
osteoblast differentiation	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of protein phosphorylation	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
response to ischemia	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
apoptotic process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
signal transduction	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
response to xenobiotic stimulus	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
ovulation cycle process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
stress-activated protein kinase signaling cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of prostaglandin secretion	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
p38MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
signal transduction in response to DNA damage	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of apoptotic process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
stress-activated MAPK cascade	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
regulation of cell cycle	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cardiac muscle contraction	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
bone development	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cellular response to sorbitol	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cellular senescence	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
negative regulation of protein phosphorylation	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA processing	TAR DNA-binding protein 43	Homo sapiens (human)
RNA splicing	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of protein stability	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of insulin secretion	TAR DNA-binding protein 43	Homo sapiens (human)
response to endoplasmic reticulum stress	TAR DNA-binding protein 43	Homo sapiens (human)
positive regulation of protein import into nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of circadian rhythm	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of apoptotic process	TAR DNA-binding protein 43	Homo sapiens (human)
negative regulation by host of viral transcription	TAR DNA-binding protein 43	Homo sapiens (human)
rhythmic process	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of cell cycle	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA destabilization	TAR DNA-binding protein 43	Homo sapiens (human)
3'-UTR-mediated mRNA stabilization	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear inner membrane organization	TAR DNA-binding protein 43	Homo sapiens (human)
amyloid fibril formation	TAR DNA-binding protein 43	Homo sapiens (human)
regulation of gene expression	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
enoyl-[acyl-carrier-protein] reductase (NADH) activity	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
protein binding	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
oxidoreductase activity	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
identical protein binding	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
NADH binding	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
protein serine/threonine kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
MAP kinase kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein tyrosine kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein binding	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
ATP binding	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein kinase binding	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
protein serine kinase activity	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
membrane	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
protein-containing complex	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
catalytic complex	Enoyl-[acyl-carrier-protein] reductase [NADH] FabI	Escherichia coli K-12
cytoplasm	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
nucleoplasm	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cytosol	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
cytoskeleton	Dual specificity mitogen-activated protein kinase kinase 6	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID751294	Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as reduction in PB18S gene expression after 48 hrs by qRT-PCR analysis	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751276	Hepatotoxicity in zebrafish larva expressing fabp10a:DsRed2 assessed as change in liver size at 3.6 to 60.2 uM measured at 6 days postfertilization by fluorescence microscopic analysis relative to control	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751280	Toxicity in zebrafish larva measured at 4 days postfertilization	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID93700	Inhibitory concentration of compound against 3'-processing of HIV-1 integrase in experiment 1	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID751296	Cytotoxicity against human KB cells after 72 hrs by Alamar Blue assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751283	Antimycobacterial activity against Mycobacterium tuberculosis ATCC 27294	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID91562	Percentage inhibition against strand transfer of HIV-1 integrase at 100 ug/mL	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID751287	Inhibition of Plasmodium falciparum FabZ using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID93707	Inhibitory concentration of compound against strand transfer of HIV-1 integrase in experiment 2	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID751289	Inhibition of Plasmodium falciparum FabI using crotonoyl-CoA as substrate preincubated for 10 mins prior to substrate addition	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751288	Inhibition of Plasmodium falciparum FabG using acetoacetyl-CoA as substrate	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751281	Antibacterial activity against Escherichia coli ATCC 8739	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751284	Inhibition of Escherichia coli FabI using 2-dodecenoyl-CoA as substrate at pH 8	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751295	Cytotoxicity against human Huh7.5 cells after 24 hrs by Cell-titerGlo luminescence assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID93705	Inhibitory concentration of compound against strand transfer of HIV-1 integrase in experiment 1	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID93702	Inhibitory concentration of compound against 3'-processing of HIV-1 integrase in experiment 2	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID91561	Percentage inhibition of compound against 3'-processing of HIV-1 integrase at 100 ug/mL	1997	Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6	Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching.
AID751291	Antiplasmodial activity against blood stage of chloroquine and pyrimethamine-resistant Plasmodium falciparum K1 after 48 hrs by [3H]-hypoxanthine incorporation assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751285	Inhibition of Staphylococcus aureus FabI using dodecenoyl ACP at pH 7.8	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751293	Antiplasmodial activity against liver stage of Plasmodium berghei ANKA expressing GFP infected in human Huh7.5 cells assessed as decrease in size at 10 uM after 48 hrs by immunofluorescence analysis	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID751286	Inhibition of Mycobacterium tuberculosis FabI using 2-dodecenoyl-CoA as substrate at pH 6.8	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1799757	Fluorescence Polarization (FP) Assay from Article 10.1016/j.chembiol.2012.05.013: \\Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.\\	2012	Chemistry & biology, Jul-27, Volume: 19, Issue:7	Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (7.14)	18.7374
1990's	1 (7.14)	18.2507
2000's	1 (7.14)	29.6817
2010's	10 (71.43)	24.3611
2020's	1 (7.14)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
digallic acid digallic acid: structure given in first source	1.99	1	benzoate ester; gallate ester
3,4-dihydroxybenzohydroxamic acid [no description available]	1.99	1	benzoic acids
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.08	1	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
triclosan [no description available]	2.08	1	aromatic ether; dichlorobenzene; monochlorobenzenes; phenols	antibacterial agent; antimalarial; drug allergen; EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; fungicide; persistent organic pollutant; xenobiotic
usnic acid [no description available]	7.07	1	benzofurans
evernic acid evernic acid: RN given refers to parent cpd	2.08	1	carbonyl compound
1,4,5,8-naphthalenetetracarboxylic acid 1,4,5,8-naphthalenetetracarboxylic acid: structure given in first source	1.99	1
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	2.08	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
physodic acid physodic acid: lichen constituent	2.73	3	carbonyl compound
5,5'-methylenedisalicylic acid 5,5'-methylenedisalicylic acid: inhibits attachment of ribosomes to microsomal membranes; RN given refers to parent cpd; structure in first source & Merck Index, 9th ed, #5934	1.99	1
atranorin atranorin: RN given refers to parent cpd; structure given in first source	1.99	1	carbonyl compound
methyl fluorone black methyl fluorone black: structure	1.99	1
stictic acid stictic acid: antioxidant from lichen, Usnea articulata; structure in first source	2.42	2	aromatic ether
diffractaic acid difractaic acid: from Lichen, Usnea steineri; active against Gram-positive, multidrug-resistant bacteria; structure in first source	1.99	1	carbonyl compound
3,4,5-trihydroxybenzohydroxamic acid [no description available]	1.99	1
pannarin pannarin: photoirradiation of above cpd leads to its decomposition which is reduced by oxygen. pannarin : A member of the class of depsidones that is 11H-dibenzo[b,e][1,4]dioxepine substituted by methyl groups at positions 1,6 and 9, chloro group at position 2, hydroxy group at position 3, formyl group at position 4, methoxy group at position 8 and an oxo group at position 11. It is a lichen metabolite isolated from several Psoroma species.	1.99	1	aldehyde; aromatic ether; depsidones; organic heterotricyclic compound; organochlorine compound; phenols	antimicrobial agent; antineoplastic agent; apoptosis inducer; lichen metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	1.93	1
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	2.07	1
(+)-usnic acid [no description available]	2.43	2	usnic acid
olivetoric acid olivetoric acid: isolated from Pseudevernia furfuracea; structure in first source	2.13	1	carbonyl compound
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	1.99	1	cinnamate ester; tannin	food component; plant metabolite
fumarprotocetraric acid fumarprotocetraric acid: RN given refers to (E)-isomer; structure given in first source	1.99	1	carbonyl compound
salazinic acid salazinic acid: lichen metabolite; structure in first source	2.42	2
norstictic acid norstictic acid: from Xanthoparmelia chlorochroa; structure in first source	2.07	1
4,5-di-O-caffeoylquinic acid [no description available]	1.99	1	quinic acid
salicylates Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.	2.5	2	monohydroxybenzoate	plant metabolite
vulpinic acid vulpinic acid: RN given refers to cpd without isomeric designation; structure given in first source; vulpinic acid refers to (E)-isomer	2.08	1	butenolide
deoxyguanosine [no description available]	2.13	1	purine 2'-deoxyribonucleoside; purines 2'-deoxy-D-ribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
8-hydroxy-2'-deoxyguanosine 8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.	2.13	1	guanosines	biomarker

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.08	1
Infections, Plasmodium [description not available]	2.08	1
Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.	2.08	1
Anemia, Fanconi [description not available]	2.13	1
Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)	2.13	1
Benign Neoplasms, Brain [description not available]	2.13	1
Astrocytoma, Grade IV [description not available]	2.13	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.13	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	7.13	1

psoromic acid

Description

Cross-References

Synonyms (52)

Drug Classes (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (47)

Molecular Functions (19)

Ceullar Components (15)

Bioassays (34)

Research

Studies (14)

Market Indicators

Research Demand Index: 21.66

Study Types

psoromic acid

Description

Cross-References

Synonyms (52)

Drug Classes (1)

Protein Targets (9)

Potency Measurements

Inhibition Measurements

Biological Processes (47)

Molecular Functions (19)

Ceullar Components (15)

Bioassays (34)

Research

Studies (14)

Market Indicators

Research Demand Index: 21.66

Study Types

Related Drugs (29)

Related Conditions (11)